JP2022541550A5 - - Google Patents
Info
- Publication number
- JP2022541550A5 JP2022541550A5 JP2022503463A JP2022503463A JP2022541550A5 JP 2022541550 A5 JP2022541550 A5 JP 2022541550A5 JP 2022503463 A JP2022503463 A JP 2022503463A JP 2022503463 A JP2022503463 A JP 2022503463A JP 2022541550 A5 JP2022541550 A5 JP 2022541550A5
- Authority
- JP
- Japan
- Prior art keywords
- level
- upper limit
- less
- pharmaceutical composition
- reference range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962876176P | 2019-07-19 | 2019-07-19 | |
| US62/876,176 | 2019-07-19 | ||
| US202063047822P | 2020-07-02 | 2020-07-02 | |
| US63/047,822 | 2020-07-02 | ||
| PCT/US2020/042820 WO2021016208A1 (en) | 2019-07-19 | 2020-07-20 | Methods of treating congenital adrenal hyperplasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022541550A JP2022541550A (ja) | 2022-09-26 |
| JP2022541550A5 true JP2022541550A5 (enExample) | 2023-07-28 |
Family
ID=74193935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022503463A Pending JP2022541550A (ja) | 2019-07-19 | 2020-07-20 | 先天性副腎過形成を処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220133742A1 (enExample) |
| EP (1) | EP3986416A4 (enExample) |
| JP (1) | JP2022541550A (enExample) |
| KR (1) | KR20220052927A (enExample) |
| CN (1) | CN114423436A (enExample) |
| AU (1) | AU2020318970B2 (enExample) |
| BR (1) | BR112022000956A2 (enExample) |
| CA (1) | CA3147891A1 (enExample) |
| MX (1) | MX2022000812A (enExample) |
| TW (1) | TW202116324A (enExample) |
| WO (1) | WO2021016208A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6585625B2 (ja) | 2014-01-21 | 2019-10-02 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト |
| KR20250022913A (ko) | 2017-08-14 | 2025-02-17 | 스프루스 바이오사이언시스 인코포레이티드 | 코티코트로핀 방출 인자 수용체 길항제 |
| CN112423747A (zh) | 2018-04-27 | 2021-02-26 | 云杉生物科学公司 | 用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法 |
| MA54395A (fr) | 2018-12-07 | 2022-03-16 | Neurocrine Biosciences Inc | Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale |
| CN114502162B (zh) | 2019-09-27 | 2025-03-28 | 纽罗克里生物科学有限公司 | Crf受体拮抗剂及使用方法 |
| MX2023001688A (es) * | 2020-08-12 | 2023-02-22 | Spruce Biosciences Inc | Metodos y composiciones para tratar el sindrome de ovario poliquistico. |
| US20240024330A1 (en) * | 2020-08-26 | 2024-01-25 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
| MD20210019A2 (ro) | 2021-04-12 | 2022-10-31 | Максим МАСЮТИН | Metodă de tratament a hiperplaziei suprarenale congenitale, cauzate de deficit de 21-hidroxilază cu debut tardiv prin regimul de glucocorticoizi adaptat individual |
| WO2023091684A1 (en) * | 2021-11-19 | 2023-05-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050085479A1 (en) * | 2003-08-27 | 2005-04-21 | Pharmacia Corporation | Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury |
| WO2005053796A1 (en) * | 2003-12-02 | 2005-06-16 | B & B Beheer Nv | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| CN101516835A (zh) * | 2006-07-19 | 2009-08-26 | 俄亥俄州立大学研究基金会 | 选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途 |
| UA96458C2 (ru) * | 2006-09-20 | 2011-11-10 | Эли Лилли Энд Компани | Тиазолпиразолопиримидиновые соединения как антагонисты рецептора crf1 |
| JP2015516979A (ja) * | 2012-04-23 | 2015-06-18 | ホルスボールマッシュマイヤー ニューロケミー ゲーエムベーハーＨｏｌｓｂｏｅｒｍａｓｃｈｍｅｙｅｒ Ｎｅｕｒｏｃｈｅｍｉｅ Ｇｍｂｈ | Ｃｒｈ過剰活性を有する患者の治療に用いるためのｃｒｈｒ１アンタゴニスト |
| JP6585625B2 (ja) * | 2014-01-21 | 2019-10-02 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 先天性副腎皮質過形成の処置のためのｃｒｆ１レセプターアンタゴニスト |
| KR20250022913A (ko) * | 2017-08-14 | 2025-02-17 | 스프루스 바이오사이언시스 인코포레이티드 | 코티코트로핀 방출 인자 수용체 길항제 |
| MX2019015318A (es) * | 2017-08-14 | 2020-07-20 | Spruce Biosciences Inc | Antagonistas del receptor del factor liberador de corticotropina. |
| CN112423747A (zh) * | 2018-04-27 | 2021-02-26 | 云杉生物科学公司 | 用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法 |
| MA54395A (fr) * | 2018-12-07 | 2022-03-16 | Neurocrine Biosciences Inc | Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale |
-
2020
- 2020-07-20 TW TW109124484A patent/TW202116324A/zh unknown
- 2020-07-20 CN CN202080065892.7A patent/CN114423436A/zh active Pending
- 2020-07-20 BR BR112022000956A patent/BR112022000956A2/pt unknown
- 2020-07-20 MX MX2022000812A patent/MX2022000812A/es unknown
- 2020-07-20 WO PCT/US2020/042820 patent/WO2021016208A1/en not_active Ceased
- 2020-07-20 EP EP20844541.1A patent/EP3986416A4/en active Pending
- 2020-07-20 CA CA3147891A patent/CA3147891A1/en active Pending
- 2020-07-20 AU AU2020318970A patent/AU2020318970B2/en active Active
- 2020-07-20 KR KR1020227005252A patent/KR20220052927A/ko active Pending
- 2020-07-20 JP JP2022503463A patent/JP2022541550A/ja active Pending
-
2022
- 2022-01-18 US US17/578,149 patent/US20220133742A1/en active Pending
-
2024
- 2024-02-09 US US18/438,060 patent/US20240261300A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025020148A5 (enExample) | ||
| IL286048B2 (en) | Abiraterone decanoate and its pharmaceutical salts, pharmaceutical preparations containing them, their uses and preparation | |
| Africander et al. | Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception | |
| Regidor et al. | Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone | |
| Sitruk-Ware | New progestogens: a review of their effects in perimenopausal and postmenopausal women | |
| CA2326654A1 (en) | Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways | |
| JP2019131587A (ja) | 子宮内膜増殖を抑制するための組成物および方法 | |
| CN1075375C (zh) | 合并应用于女性避孕的具黄体酮拮抗作用和抗雌激素作用的化合物 | |
| JP2007535922A5 (enExample) | ||
| JP2006527193A5 (enExample) | ||
| JP2011502172A5 (enExample) | ||
| JP2021512852A5 (enExample) | ||
| CN103298343A (zh) | 类固醇和糖皮质激素受体拮抗剂组合疗法 | |
| Davtyan | Four generations of progestins in oral contraceptives | |
| CN110997667A (zh) | 促肾上腺皮质激素释放因子受体拮抗剂 | |
| JP2008534533A5 (enExample) | ||
| Pluchino et al. | One-year therapy with 10 mg/day DHEA alone or in combination with HRT in postmenopausal women: effects on hormonal milieu | |
| JP2018062530A (ja) | プロゲステロン依存性病態を処置する方法およびその組成物 | |
| IL312515A (en) | Bispecific cd16a binders | |
| Schane et al. | ORAL PROGESTATIONAL ACTIVITY OF SPIRONOLACTONE1 | |
| WO2023163945A1 (en) | Treatment of congenital adrenal hyperplasia and polycystic ovary syndrome | |
| Noori et al. | Effects of estrogen and progesterone used in oral contraceptive pills: A review | |
| JP2005513024A5 (enExample) | ||
| IL312514A (en) | Corticosteroid reduction in treatment with anti-cd38 antibodies | |
| JP2024540304A5 (enExample) |